|
| | DIHYDROERGOTAMINE MESYLATE Basic information |
| | DIHYDROERGOTAMINE MESYLATE Chemical Properties |
| Melting point | 232°C | | refractive index | -20 ° (C=0.25, JP Method) | | storage temp. | Store at RT | | solubility | methanol: 21 mg/mL | | form | powder | | color | white | | Merck | 14,3174 | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months. | | CAS DataBase Reference | 6190-39-2(CAS DataBase Reference) |
| Hazard Codes | Xn | | Risk Statements | 20/21/22 | | Safety Statements | 36 | | RIDADR | 1544 | | WGK Germany | 3 | | RTECS | KE7920000 | | HazardClass | 6.1(b) | | PackingGroup | III | | HS Code | 2939690000 |
| | DIHYDROERGOTAMINE MESYLATE Usage And Synthesis |
| Description | Dihydroergotamine mesylate (6190-39-2) is a full agonist at serotonin 5HT1B and 5HT1D receptors, IC50= 2 and 2.2 nM respectively1 and also at 5HT1A and 5HT1F receptors2. One of the oldest agents for treatment of migraine.3 Also acts as a potent vasoconstrictor and alpha-adrenergic antagonist.4 | | Chemical Properties | White to Off-White Solid | | Uses | α-Androgenic blocker with selective venoconstrictor properties. Also binds to serotonin 5HT1-receptors. Antimigraine. | | Uses | vasoconstrictor, antimigraine | | Uses | Agonist at vascular serotonin receptors; partial agonist at alpha-adrenergic and dopamine D2 receptors | | Definition | ChEBI: The methanesulfonic acid salt of dihydroergotamine, a semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine. Both the mesylate and the tartrate salts are used for the treatment of migraine and orthostatic hypotens
on. | | Brand name | D.H.E. 45 (Valeant); Migranal (Valeant)
. | | Biological Activity | Partial α -adrenergic agonist. Partial D 2 dopaminergic receptor agonist. Competitive 5-HT antagonist. | | storage | Room temperature | | References | Lesage et al. (1998), Agnostic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines; J. Pharmacol., 123 1655
Silberstein (1997), The pharmacology of ergotamine and dihydroergotamine; Headache, 37 Suppl 1 S15
Silberstein and McCrory (2003), Ergotamine and dihydroergotamine: history, pharmacology, and efficacy; Headache, 43 144
Lipton (1997), Ergotamine tartrate and dihydroergotamine mesylate: safety profiles; Headache, 37 Suppl.1 S33 |
| | DIHYDROERGOTAMINE MESYLATE Preparation Products And Raw materials |
|
